The firm placed 65 sample-to-answer systems under contract in the second quarter compared to 35 systems in the prior-year quarter.
Product revenues were up 63 percent year over year, while research revenues rose twelvefold. The company placed nine new T2Dx instruments in Q2 2018.
The company's life sciences segment had $1.08 billion in revenues, driven by strong performance of the preanalytical systems, diagnostic systems, and biosciences units.
The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.
The company posted $29.3 million in revenues for the quarter, including $25 million from its tuberculosis business, which grew 17 percent year over year.
Revenues for Roche Diagnostics totaled CHF 6.26 billion for H1, driven primarily by demand for immunodiagnostic solutions.
The company acknowledged the opening up of exclusive insurer contracts may negatively impact revenues next year.
The company's revenues totaled $6.08 billion, up from $4.99 billion during Q2 of 2017.
The firm said that its average revenue per clinical genetic test decreased by almost 4 percent to $318, primarily due to changes in Medicare reimbursement and regulation.